Deciphera Pharmaceuticals Inc   (DCPH)
Other Ticker:  
Price: $12.6800 $0.06 0.475%
Day's High: $12.75 Week Perf: -0.39 %
Day's Low: $ 12.49 30 Day Perf: -12.79 %
Volume (M): 468 52 Wk High: $ 22.76
Volume (M$): $ 5,929 52 Wk Avg: $15.21
Open: $12.57 52 Wk Low: $12.33

 Market Capitalization (Millions $) 1,078
 Shares Outstanding (Millions) 85
 Employees 288
 Revenues (TTM) (Millions $) 144
 Net Income (TTM) (Millions $) -187
 Cash Flow (TTM) (Millions $) -29
 Capital Exp. (TTM) (Millions $) 1

Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals Inc is a biopharmaceutical company that is focused on discovering, developing, and commercializing kinase inhibitor therapies for the treatment of patients with cancer. The company was established in 2003 and is based in Waltham, Massachusetts.

The core technology of Deciphera Pharmaceuticals is its proprietary kinase switch control inhibitor platform (KSCI). This technology enables the company to design highly selective inhibitors that target specific kinases and to optimize the molecules with respect to potency, safety, and pharmacokinetics.

The company's lead product candidate is Ripretinib (DCC-2618), an inhibitor of KIT and PDGFR' kinases that is being evaluated for the treatment of patients with gastrointestinal stromal tumors (GISTs). GISTs are rare cancerous tumors that arise in the digestive tract and account for approximately 1% of all gastrointestinal tumors.

In addition to Ripretinib, Deciphera Pharmaceuticals has a pipeline of early-stage product candidates that are being developed for the treatment of a variety of solid tumor indications. These include inhibitors of kinases such as FGFR, CSF1R, and VEGFR.

Deciphera Pharmaceuticals has collaborated with several pharmaceutical companies, including Eli Lilly and Company, Sanofi, and Takeda Pharmaceutical Company Limited, to develop and commercialize its product candidates. The company has also entered into licensing agreements with other companies to further develop its KSCI platform and expand its product portfolio.

The company has received several awards and recognitions for its innovative technology and drug development efforts. In 2019, Deciphera Pharmaceuticals was named one of the top 50 most innovative companies in the world by Fast Company. The company is also listed on the NASDAQ Global Select Market under the ticker symbol "DCPH."

   Company Address: 200 Smith Street Waltham 2451 MA
   Company Phone Number: 209-6400   Stock Exchange / Ticker: NASDAQ DCPH
   DCPH is expected to report next financial results on November 02, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Renovaro Biosciences Inc

Headline: Renovaro Biosciences Inc Continues to Report Zero Revenue, Reflecting Limited Growth in Q2 Fiscal Year 2023 Pharmaceutical preparations company experiences no change in revenue compared to previous year, raises concerns over lack of expansion prospects.

Renovaro Biosciences Inc, a major pharmaceutical preparations company, has released its financial report for the fiscal period ending June 30, 2023. During this period, the company experienced zero gain per share, an improvement compared to the same period a year ago when it reported a gain of $0.33 per share. It also represents an increase from the preceding financial reporting period when the company reported a loss of $0.08 per share.
In terms of revenue, Renovaro Biosciences Inc did not experience any change compared to the corresponding financial reporting period a year ago. The revenue remained at $0.00 million, and there was no sequential change either. This stability in revenue could be an area of concern for the company, as it suggests a lack of growth or expansion in its operations.

Immuron Limited

Immuron Limited reports decreased revenue and widened net loss in Q4 2023

In the financial fourth quarter of 2023, Immuron Limited, a major pharmaceutical preparations company, reported its financial results, which revealed a decrease in revenue and widened net loss. These figures mark a notable change compared to the corresponding financial reporting period from the previous year. This article aims to examine the context behind Immuron Limited's financial results, including its stock performance and implications for investors.
Financial Results:
Immuron Limited disclosed a revenue of $1.480365 million in the financial fourth quarter of 2023 after experiencing a net loss of $-3.787 million. These figures signify a departure from balanced books in the corresponding period a year earlier. Additionally, in the financial year 2023, the company announced a loss of $-3.79 million alongside a revenue of $1.48 million. In comparison to the prior financial year, the net loss per share has widened from $-1.25 to $-1.66, indicating a financial decline. However, it is important to note that the net loss remained unchanged from $0.00 million a year earlier.

Procyon Corporation

Observing the fourth quarter of 2023 numbers, Procyon Corporation reveals concerning revenue decline

Procyon Corporation recently released their financial results for the fourth quarter of the 2023 earnings season. While the company reported unaltered earnings per share (EPS), a decline in revenue and other key indicators raises concerns about the company's future performance. This article aims to interpret the financial results and discuss their potential impact on Procyon Corporation going forward.
1. Earnings per Share (EPS) and Revenue Performance:
Procyon Corporation maintained an EPS of $0.00 in the fourth quarter, suggesting stability in their profitability. However, the company experienced a modest revenue decline of -0.589% year-on-year, amounting to $1.20 million. This decline sets Procyon apart from the rest of the Major Pharmaceutical Preparations industry, which recorded a revenue improvement during the same period.

Innovation Pharmaceuticals Inc

Revitalizing Growth: Innovation Pharmaceuticals Inc's Revenue Stagnant, But Positive Signs Emerge

Innovation Pharmaceuticals Inc, a pharmaceutical company, recently announced its financial results for the fiscal year ending June 30, 2023. During this period, the company achieved a break-even point of $0.00 per share, which was the same as the previous year and the previous quarter.
However, the company did not generate any revenue during this quarter, remaining at $0.00 million, the same as the previous year and quarter. This indicates that there was no growth in the company's revenue during this period.
Additionally, Innovation Pharmaceuticals Inc reported a net shortfall of $-0.681 million for the fiscal year ending June 30, 2023. This is a significant improvement compared to the deficit of $-1.626 million reported in the same quarter a year ago. Although still in a shortfall, the company has managed to reduce its losses, which may indicate positive efforts in managing their expenses.

Palatin Technologies Inc

Palatin Technologies Inc Defies the Odds with Explosive Revenue Growth in Q4 2023, While Major Pharmaceutical Preparations Companies Struggle to Turn Profitable

Financial News Report:
Palatin Technologies Inc Reports Strong Revenue Growth in Q4 2023, Despite Stock Deficit
Palatin Technologies Inc (PTN) has announced a substantial revenue advancement of 109.038% year on year to $1.76 million in the fourth quarter of 2023. However, the company posted a deficit per stock at $-0.98. Despite the stock deficit, PTN's revenue experienced significant growth compared to its peers in the Major Pharmaceutical Preparations industry. Most corporations in this industry saw an average revenue advance of 3.04% during the same period.
In comparison to the preceding reporting period, PTN's revenue surged by 47.359% from $1.20 million and the deficit improved from $0.00 per share. This strong revenue growth indicates a positive trend for Palatin Technologies Inc.


Deciphera Pharmaceuticals Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com